

Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB: 5/15/1992
Gender: Male
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Collection Date: 00/00/0000 00:00

Aortopathy Panel, Sequencing and Deletion/Duplication
ARUP test code 2006540

Aortopathy Panel Specimen whole Blood

Aortopathy Panel Interpretation

Positive
RESULT
One likely pathogenic variant was detected in the TGFBR1 gene.

LIKELY PATHOGENIC VARIANT
Gene: TGFBR1 (NM_004612.4)
Nucleic Acid Change: c.934G>A; Heterozygous
Amino Acid Alteration: p.Gly312Ser
Inheritance: Autosomal dominant

INTERPRETATION
One likely pathogenic variant, c.934G>A; p.Gly312Ser, was detected in the TGFBR1 gene by massively parallel sequencing. Pathogenic variants in TGFBR1 are associated with autosomal dominant Loeys-Dietz syndrome 1 (MIM: 609192). This result is consistent with a diagnosis of Loeys-Dietz syndrome. This individual's offspring have a 50 percent chance of inheriting the likely pathogenic variant.

Please refer to the background information included in this report for a list of the genes analyzed, methodology, and limitations of this test.

Evidence for variant classification:
The TGFBR1 c.934G>A; p.Gly312Ser variant (rs760079636) is reported in the literature in numerous individuals affected with symptoms of an aortopathy disorder and has been reported to segregate with disease in several small kindreds (Arnaud 2019, Jondeau 2016, Luo 2016, Nickol 2022, Singh 2006, Tran-Fadulu 2009, Yang 2020). This variant is only observed on one allele in the Genome Aggregation Database (v2.1.1), indicating it is not a common polymorphism. Computational analyses predict that this variant is deleterious (REVEL: 0.964). Based on available information, this variant is considered to be likely pathogenic.

RECOMMENDATIONS
Genetic consultation is indicated, including a discussion of medical screening and management. At-risk family members should be offered testing for the identified likely pathogenic TGFBR1 variant (Familial Targeted Sequencing, ARUP test code 3005867).

COMMENTS
Likely benign and benign variants are not reported. Variants in the following region(s) may not be detected by NGS with sufficient confidence in this sample due to technical limitations: None

H=High, L=Low, *=Abnormal, C=Critical

REFERENCES

Arnaud et al. Genetic diversity and pathogenic variants as possible predictors of severity in a French sample of nonsyndromic heritable thoracic aortic aneurysms and dissections (nshTAAD). Genet Med. 2019 Sep;21(9):2015-2024. PMID: 30739908.

Jondeau G et al. International Registry of Patients Carrying TGFBR1 or TGFBR2 Mutations: Results of the MAC (Montalcino Aortic Consortium). Circ Cardiovasc Genet. 2016 Dec;9(6):548-558. PMID: 27879313.

Luo M et al. Genetic testing of 10 patients with features of Loeys-Dietz syndrome. Clin Chim Acta. 2016 May 1;456:144-148. PMID: 26877057.

Nickol JL et al. Case report of Loeys-Dietz syndrome presenting with coronary artery aneurysm. Eur Heart J Case Rep. 2022 Sep 15;6(10):ytac383. PMID: 36237225.

Singh KK et al. TGFBR1 and TGFBR2 mutations in patients with features of Marfan syndrome and Loeys-Dietz syndrome. Hum Mutat. 2006 Aug;27(8):770-7. PMID: 16799921.

Tran-Fadulu V et al. Analysis of multigenerational families with thoracic aortic aneurysms and dissections due to TGFBR1 or TGFBR2 mutations. J Med Genet. 2009 Sep;46(9):607-13. PMID: 19542084.

Yang H et al. Genetic profiling and cardiovascular phenotypic spectrum in a Chinese cohort of Loeys-Dietz syndrome patients. Orphanet J Rare Dis. 2020 Jan 8;15(1):6. PMID: 31915033.

This result has been reviewed and approved by Yuan Ji, Ph.D.
BACKGROUND INFORMATION: Aortopathy Panel, Sequencing and Deletion/Duplication

CHARACTERISTICS: Aortopathy disorders are associated with aneurysm, dissection and/or rupture of the aorta. Clinical presentation may include thoracic aortic aneurysm and dissection (TAAD). Syndromic forms include Marfan syndrome (MFS), Loeys-Dietz syndrome (LDS), Ehlers-Danlos syndrome (EDS: classic, vascular, and kyphoscoliotic types), Shprintzen-Goldberg syndrome, multisystemic smooth muscle dysfunction syndrome, Meester-Loeys syndrome, congenital contractural arachnodactyly (CCA), arterial tortuosity syndrome, periventricular nodular heterotopia 1, cutis laxa type 1B, juvenile polyposis/hereditary hemorrhagic telangiectasia syndrome, and aortic valve disease 1. Homocystinuria due to cystathionine beta-synthase deficiency (HCY) has phenotypic overlap with MFS.

EPIDEMIOLOGY: The prevalence of Marfan syndrome (MFS) is 1 in 5,000 to 1 in 10,000; HCY is 1 in 1,800 to 1 in 335,000 depending on the ethnic population; EDS, classic type (CEDS, type I/II) is 1 in 20,000; EDS, vascular type (VEDS, type IV) is at least 1 in 200,000. TAAD has an incidence of 9-16/100,000 individuals/year and is familial in approximately 20 percent of cases.

CAUSE: Pathogenic germline variants in genes associated with aortopathy disorders

INHERITANCE: Commonly autosomal dominant. X-linked for BGN and FLNA. Autosomal recessive for CBS, EFEMP2, PLOD1, and SLC2A10.

PENETRANCE: Complete for MFS, VEDS, PLOD1-associated KEDS, CCA, and LDS, with rare exceptions; reduced for TAAD and CEDS.

GENES TESTED: ACTA2, BGN, CBS*, COL1A1, COL1A2*, COL3A1, COL5A1*, COL5A2, EFEMP2, FBN1, FBN2, FLNA, FOXE3*, LOX, MFAP5, MYH11, MYLK*, NOTCH1*, PLOD1, PRKG1, SKI, SLC2A10, SMAD2, SMAD3,

H=High, L=Low, *=Abnormal, C=Critical

SMAD4, TGFβ2, TGFβ3**, TGFβR1, TGFβR2.

*One or more exons are not covered by sequencing and/or deletion/duplication analysis for the indicated gene; see limitations section below.

**Deletion/duplication detection is not available for this gene.

METHODOLOGY: Probe hybridization-based capture of all coding exons and exon-intron junctions of the targeted genes, followed by massively parallel sequencing. Sanger sequencing was performed as necessary to fill in regions of low coverage and to confirm reported variants that do not meet acceptable quality metrics. A proprietary bioinformatic algorithm was used to detect large (single exon-level or larger) deletions or duplications in the indicated genes. Large deletions/duplications were confirmed using an orthogonal exon-level microarray. Human genome build 19 (Hg 19) was used for data analysis.

ANALYTICAL SENSITIVITY: The analytical sensitivity is approximately 99 percent for single nucleotide variants (SNVs) and greater than 93 percent for insertions/duplications/deletions (indels) from 1-10 base pairs in size. Indels greater than 10 base pairs may be detected, but the analytical sensitivity may be reduced. Deletions of 2 exons or larger are detected with sensitivity greater than 97 percent; single exon deletions are detected with 62 percent sensitivity. Duplications of 3 exons or larger are detected at greater than 83 percent sensitivity. Specificity is greater than 99.9 percent for all variant classes.

LIMITATIONS: A negative result does not exclude a heritable aortopathy disorder. This test only detects variants within the coding regions and intron-exon boundaries of the targeted genes. Deletions/duplications/insertions of any size may not be detected by massively parallel sequencing. Regulatory region variants and deep intronic variants will not be identified. Precise breakpoints for large deletions or duplications are not determined in this assay and single exon deletions/duplications may not be detected based on the breakpoints of the rearrangement. The actual breakpoints for the deletion or duplication may extend beyond or be within the exon(s) reported. This test is not intended to detect duplications of 2 or fewer exons in size, though these may be identified. Single exon deletions are reported but called at a lower sensitivity. Diagnostic errors can occur due to rare sequence variations. In some cases, variants may not be identified due to technical limitations caused by the presence of pseudogenes, repetitive, or homologous regions. This test is not intended to detect low-level mosaic or somatic variants, gene conversion events, complex inversions, translocations, mitochondrial DNA (mtDNA) mutations, or repeat expansions. Interpretation of this test result may be impacted if this patient has had an allogeneic stem cell transplantation. Noncoding transcripts were not analyzed.

The following regions are not sequenced due to technical limitations of the assay:

CBS(NM_001321072) exon(s) 1
COL5A1(NM_000093) exon(s) 1
COL5A1(NM_001278074) exon(s) 1
FOXE3(NM_012186) partial exon(s) 1(Chr1:47882098-47882163)

Single exon deletions/duplications will not be called for the following exons:

CBS(NM_001321072) 1; COL1A2(NM_000089) 3; COL5A1(NM_000093) 1;
COL5A1(NM_001278074) 1; MYLK(NM_053025) 13; MYLK(NM_001321309) 12;
MYLK(NM_053026) 12; MYLK(NM_053027) 13; MYLK(NM_053028) 12;
NOTCH1(NM_017617) 1

This test was developed and its performance characteristics

H=High, L=Low, *=Abnormal, C=Critical



determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

VERIFIED/REPORTED DATES				
Procedure	Accession	Collected	Received	Verified/Reported
Aortopathy Panel Specimen	24-040-133363	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Aortopathy Panel Interpretation	24-040-133363	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical